Janus Kinase Inhibitor Use After Liver Transplantation Is Associated With Sustained Malignancy and Thromboembolic Risk: A Propensity Score-Matched Real-World Cohort Study (ACG 2026) - Aug 29, 2026 - Abstract #P1614; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "JAKi exposure included tofacitinib, ruxolitinib, upadacitinib, or baricitinib recorded on or after documentation of LT status. Among 74,576 adults with LT, 238 received JAKi and 74,338 did not. After PSM, 232 patients were retained in each cohort with balanced demographic and clinical characteristics. JAKi use was associated with higher malignancy risk at 1 year (23.3% vs 12.1%; HR 2.33, 95% CI 1.48â3.69; p< 0.001), which persisted at 5 years (26.7% vs 17.2%; HR 2.15, 95% CI 1.44â3.22; p< 0.001)."
Clinical • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Dyslipidemia • Genetic Disorders • Graft versus Host Disease • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Myeloproliferative Neoplasm • Myocardial Infarction • Nephrology • Obesity • Oncology • Transplant Rejection • Transplantation • Venous Thromboembolism
|
|
Sarpong Boateng MD MPH 1; Guy Loic Nguefang MD 2; Yussif Issaka MD MPH 3; Chimezirim Ezeano MD MPH 4; Ridwan Lawal MBBS 5; Bright Nwatamole MBBS 6; Eunice K. Omeludike MD 7; Basile Njei MD MPH PhD 8
|